| Primary | Change in Pain as Assessed by the Shoulder Pain and Disability Index (SPADI) | SPADI is a self-administered questionnaire that measures a combination of pain and functional disability. SPADI is scored from 0 to 100 with a high score representing more pain and disability. The change in score is reported as [(SPADI at Week 4) - (SPADI at baseline)] -- a negative value indicates pain and disability decreased over time. | Data was collected and analyzed for participants who completed both baseline and week 4 questionnaire. | Posted | | Mean | Standard Deviation | score on a scale | | Baseline, Week 4 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG000-37.8± 22.49
- OG001-9.5± 17.69
|
|
| |
| Primary | Change in Pain as Assessed by the Shoulder Pain and Disability Index (SPADI) | SPADI is a self-administered questionnaire that measures a combination of pain and functional disability. SPADI is scored from 0 to 100 with a high score representing more pain and disability. The change in score is reported as [(SPADI at Week 12) - (SPADI at baseline)] -- a negative value indicates pain and disability decreased over time. | Data was collected and analyzed for participants who completed both baseline and week 12 questionnaire. | Posted | | Mean | Standard Deviation | score on a scale | | Baseline, Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Primary | Change in Pain as Assessed by the Shoulder Pain and Disability Index (SPADI) | SPADI is a self-administered questionnaire that measures a combination of pain and functional disability. SPADI is scored from 0 to 100 with a high score representing more pain and disability. The change in score is reported as [(SPADI at 6 months) - (SPADI at baseline)] -- a negative value indicates pain and disability decreased over time. | Data was collected and analyzed for participants who completed both baseline and week 24 questionnaire. | Posted | | Mean | Standard Deviation | score on a scale | | Baseline, week 24 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Pain Intensity as Assessed by the Visual Analog Scale (VAS) | Visual Analog Scale (VAS) is scored on a 100mm horizontal line that represents pain intensity, from 0mm to 100mm, with a higher score corresponding to increased pain intensity. The change in pain intensity will be reported as [(VAS at week 4) - (VAS at baseline)] - a negative value indicates a decrease in pain intensity. | Data was collected and analyzed for participants who completed both baseline and week 4 questionnaire. | Posted | | Mean | Standard Deviation | mm | | Baseline, week 4 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Pain Intensity as Assessed by the Visual Analog Scale (VAS) | Visual Analog Scale (VAS) is scored on a 100mm horizontal line that represents pain intensity, from 0mm to 100mm, with a higher score corresponding to increased pain intensity. The change in pain intensity will be reported as [(VAS at week 12) - (VAS at baseline)] - a negative value indicates a decrease in pain intensity. | Data was collected and analyzed for participants who completed both baseline and week 12 questionnaire. | Posted | | Mean | Standard Deviation | mm | | Baseline, week 12 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Pain Intensity as Assessed by the Visual Analog Scale (VAS) | Visual Analog Scale (VAS) is scored on a 100mm horizontal line that represents pain intensity, from 0mm to 100mm, with a higher score corresponding to increased pain intensity. The change in pain intensity will be reported as [(VAS at 6 months) - (VAS at baseline)] - a negative value indicates a decrease in pain intensity. | | Posted | | Mean | Standard Deviation | mm | | Baseline, week 24 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Shoulder Function as Assessed by the American Shoulder and Elbow Surgeons (ASES) Score | The American shoulder and elbow surgeons (ASES) score assess shoulder function. ASES Score ranges from 0 to 100, with a score of 0 indicating a worse shoulder condition and a score of 100 indicating a better shoulder condition. The change in score is reported as [(ASES score at week 4) - (ASES score at baseline)] - a positive value indicates an improvement in shoulder function over time. | Data was collected and analyzed for participants who completed both baseline and week 4 ASES Score. | Posted | | Mean | Standard Deviation | score on a scale | | Baseline, Week 4 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Shoulder Function as Assessed by the American Shoulder and Elbow Surgeons (ASES) Score | The American shoulder and elbow surgeons (ASES) score assess shoulder function. ASES Score ranges from 0 to 100, with a score of 0 indicating a worse shoulder condition and a score of 100 indicating a better shoulder condition. The change in score is reported as [(ASES score at week 12) - (ASES score at baseline)] - a positive value indicates an improvement in shoulder function over time. | Data was collected and analyzed for participants who completed both baseline and week 12 ASES Score. | Posted | | Mean | Standard Deviation | score on a scale | | Baseline, Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in American Shoulder and Elbow Surgeons (ASES) Score | The American shoulder and elbow surgeons (ASES) score assess shoulder function. ASES Score ranges from 0 to 100, with a score of 0 indicating a worse shoulder condition and a score of 100 indicating a better shoulder condition. The change in score is reported as [(ASES score at week 24) - (ASES score at baseline)] - a positive value indicates an improvement in shoulder function over time | | Posted | | Mean | Standard Deviation | score on a scale | | Baseline, Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Range of Motion as Assessed by the Passive Range of Motion (PROM) Assessment Using a Goniometer (Abduction Internal Rotation) | A goniometer will be used to measure range of motion during the PROM assessment. The goniometer measures the angle between the beginning position and the ending position of available motion, and the result is reported in degrees. Change from baseline will be calculated, with a positive values indicating improved range of motion. | Data was collected and analyzed for participants who completed both baseline and week 4 visit. | Posted | | Mean | Standard Deviation | degrees | | Baseline, Week 4 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Range of Motion as Assessed by the Passive Range of Motion (PROM) Assessment Using a Goniometer (Abduction Internal Rotation) | A goniometer will be used to measure range of motion during the PROM assessment. The goniometer measures the angle between the beginning position and the ending position of available motion, and the result is reported in degrees. Change from baseline will be calculated, with a positive values indicating improved range of motion. | Data was collected and analyzed for participants who completed both baseline and week 12 visit. | Posted | | Mean | Standard Deviation | degrees | | Baseline, Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Range of Motion as Assessed by the Passive Range of Motion (PROM) Assessment Using a Goniometer (Abduction Internal Rotation) | A goniometer will be used to measure range of motion during the PROM assessment. The goniometer measures the angle between the beginning position and the ending position of available motion, and the result is reported in degrees. Change from baseline will be calculated, with a positive values indicating improved range of motion. | Data was collected and analyzed for participants who completed both baseline and week 24 visit. | Posted | | Mean | Standard Deviation | degrees | | Baseline, Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Range of Motion as Assessed by the Passive Range of Motion (PROM) Assessment Using a Goniometer (Abduction External Rotation) | A goniometer will be used to measure range of motion during the PROM assessment. The goniometer measures the angle between the beginning position and the ending position of available motion, and the result is reported in degrees. Change from baseline will be calculated, with a positive values indicating improved range of motion. | Data was collected and analyzed for participants who completed both baseline and week 4 visit. | Posted | | Mean | Standard Deviation | degrees | | Baseline, Week 4 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Range of Motion as Assessed by the Passive Range of Motion (PROM) Assessment Using a Goniometer (Abduction External Rotation) | A goniometer will be used to measure range of motion during the PROM assessment. The goniometer measures the angle between the beginning position and the ending position of available motion, and the result is reported in degrees. Change from baseline will be calculated, with a positive values indicating improved range of motion. | Data was collected and analyzed for participants who completed both baseline and week 12 visit. | Posted | | Mean | Standard Deviation | degrees | | Baseline, Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Range of Motion as Assessed by the Passive Range of Motion (PROM) Assessment Using a Goniometer (Abduction External Rotation) | A goniometer will be used to measure range of motion during the PROM assessment. The goniometer measures the angle between the beginning position and the ending position of available motion, and the result is reported in degrees. Change from baseline will be calculated, with a positive values indicating improved range of motion. | Data was collected and analyzed for participants who completed both baseline and week 24 visit. | Posted | | Mean | Standard Deviation | degrees | | Baseline, Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Range of Motion as Assessed by the Passive Range of Motion (PROM) Assessment Using a Goniometer (Forward Elevation) | A goniometer will be used to measure range of motion during the PROM assessment. The goniometer measures the angle between the beginning position and the ending position of available motion, and the result is reported in degrees. Change from baseline will be calculated, with a positive values indicating improved range of motion. | Data was collected and analyzed for participants who completed both baseline and week 4 visit. | Posted | | Mean | Standard Deviation | degrees | | Baseline, Week 4 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Range of Motion as Assessed by the Passive Range of Motion (PROM) Assessment Using a Goniometer (Forward Elevation) | A goniometer will be used to measure range of motion during the PROM assessment. The goniometer measures the angle between the beginning position and the ending position of available motion, and the result is reported in degrees. Change from baseline will be calculated, with a positive values indicating improved range of motion. | Data was collected and analyzed for participants who completed both baseline and week 12 visit. | Posted | | Mean | Standard Deviation | degrees | | Baseline, Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Range of Motion as Assessed by the Passive Range of Motion (PROM) Assessment Using a Goniometer (Forward Elevation) | A goniometer will be used to measure range of motion during the PROM assessment. The goniometer measures the angle between the beginning position and the ending position of available motion, and the result is reported in degrees. Change from baseline will be calculated, with a positive values indicating improved range of motion. | Data was collected and analyzed for participants who completed both baseline and week 24 visit. | Posted | | Mean | Standard Deviation | degrees | | Baseline, Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Range of Motion as Assessed by the Passive Range of Motion (PROM) Assessment Using a Goniometer (Abduction) | A goniometer will be used to measure range of motion during the PROM assessment. The goniometer measures the angle between the beginning position and the ending position of available motion, and the result is reported in degrees. Change from baseline will be calculated, with a positive values indicating improved range of motion. | Data was collected and analyzed for participants who completed both baseline and week 4 visit. | Posted | | Mean | Standard Deviation | degrees | | Baseline, Week 4 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Range of Motion as Assessed by the Passive Range of Motion (PROM) Assessment Using a Goniometer (Abduction) | A goniometer will be used to measure range of motion during the PROM assessment. The goniometer measures the angle between the beginning position and the ending position of available motion, and the result is reported in degrees. Change from baseline will be calculated, with a positive values indicating improved range of motion. | Data was collected and analyzed for participants who completed both baseline and week 12 visit. | Posted | | Mean | Standard Deviation | degrees | | Baseline, Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Range of Motion as Assessed by the Passive Range of Motion (PROM) Assessment Using a Goniometer (Abduction) | A goniometer will be used to measure range of motion during the PROM assessment. The goniometer measures the angle between the beginning position and the ending position of available motion, and the result is reported in degrees. Change from baseline will be calculated, with a positive values indicating improved range of motion. | Data was collected and analyzed for participants who completed both baseline and week 24 visit. | Posted | | Mean | Standard Deviation | degrees | | Baseline, Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Range of Motion as Assessed by the Passive Range of Motion (PROM) Assessment Using a Goniometer (External Rotation) | A goniometer will be used to measure range of motion during the PROM assessment. The goniometer measures the angle between the beginning position and the ending position of available motion, and the result is reported in degrees. Change from baseline will be calculated, with a positive values indicating improved range of motion. | Data was collected and analyzed for participants who completed both baseline and week 4 visit. | Posted | | Mean | Standard Deviation | degrees | | Baseline, Week 4 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Range of Motion as Assessed by the Passive Range of Motion (PROM) Assessment Using a Goniometer (External Rotation) | A goniometer will be used to measure range of motion during the PROM assessment. The goniometer measures the angle between the beginning position and the ending position of available motion, and the result is reported in degrees. Change from baseline will be calculated, with a positive values indicating improved range of motion. | Data was collected and analyzed for participants who completed both baseline and week 12 visit. | Posted | | Mean | Standard Deviation | degrees | | Baseline, Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Range of Motion as Assessed by the Passive Range of Motion (PROM) Assessment Using a Goniometer (External Rotation) | A goniometer will be used to measure range of motion during the PROM assessment. The goniometer measures the angle between the beginning position and the ending position of available motion, and the result is reported in degrees. Change from baseline will be calculated, with a positive values indicating improved range of motion. | Data was collected and analyzed for participants who completed both baseline and week 24 visit. | Posted | | Mean | Standard Deviation | degrees | | Baseline, Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Range of Motion as Assessed by the Passive Range of Motion (PROM) Assessment Using a Goniometer (Neutral Internal Rotation) | A goniometer will be used to measure range of motion during the PROM assessment. The goniometer measures the angle between the beginning position and the ending position of available motion, and the result is reported in degrees. Change from baseline will be calculated, with a positive values indicating improved range of motion. | Data was collected and analyzed for participants who completed both baseline and week 4 visit. | Posted | | Mean | Standard Deviation | degrees | | Baseline, Week 4 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Range of Motion as Assessed by the Passive Range of Motion (PROM) Assessment Using a Goniometer (Neutral Internal Rotation) | A goniometer will be used to measure range of motion during the PROM assessment. The goniometer measures the angle between the beginning position and the ending position of available motion, and the result is reported in degrees. Change from baseline will be calculated, with a positive values indicating improved range of motion. | Data was collected and analyzed for participants who completed both baseline and week 12 visit. | Posted | | Mean | Standard Deviation | degrees | | Baseline, Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |
| Secondary | Change in Range of Motion as Assessed by the Passive Range of Motion (PROM) Assessment Using a Goniometer (Neutral Internal Rotation) | A goniometer will be used to measure range of motion during the PROM assessment. The goniometer measures the angle between the beginning position and the ending position of available motion, and the result is reported in degrees. Change from baseline will be calculated, with a positive values indicating improved range of motion. | Data was collected and analyzed for participants who completed both baseline and week 24 visit. | Posted | | Mean | Standard Deviation | degrees | | Baseline, Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Intra-articular Injection of Corticosteroid Plus Lidocaine | Participants will receive a corticosteroid injection consisting of Triamcinolone 20 mg (1cc) with Lidocaine 10 mg/ml (5 cc). Corticosteroid: Triamcinolone 20 mg (1cc) Lidocaine: Lidocaine 10 mg/mL (5cc) | | OG001 | Intra-articular Injection of ActiveMatrix Plus Lidocaine | Participants will receive an injection consisting of ActiveMatrix (1cc; Skye Biologics, Inc.) with Lidocaine 10 mg/ml (5cc). ActiveMatrix: 1cc ActiveMatrix (Skye Biologics, Inc.) Lidocaine: Lidocaine 10 mg/mL (5cc) |
| |